GSK has resubmitted its NDA to the FDA for tebipenem HBr, an oral carbapenem for complicated UTIs, backed by positive phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback